Adaptam Therapeutics

adaptamtx.com ↗ ·San Sebastián ·Pre-seed

Adaptam Therapeutics is a Spanish biotech spin-off from CIC bioGUNE developing first-in-class antibody-based cancer immunotherapies (including antibody-drug conjugates and bispecific antibodies) that target novel glyco-immune checkpoints, such as Siglecs, on immunosuppressive myeloid cells in the tumor microenvironment. Founded in 2023, it raised a €3M pre-seed round in October 2025 led by Criteria Bio Ventures.

Founded

2023

Founders

Total funds raised

€3M

SectorsBiotech, Oncology, Immuno-oncology, Therapeutic antibodies Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Asís Palazón

Founder, CEO & CSO

Global models 5

Pionyr Immunotherapeutics

United States · www.pionyrtx.com ↗

Developed antibody therapeutics rebalancing myeloid cells in the tumor microenvironment, the closest large-scale comparable to Adaptam's myeloid-targeting antibody approach.

$352MComparable

OncoResponse

United States · oncoresponse.com ↗

Immuno-oncology biotech developing antibodies against targets linked to immunosuppressive myeloid biology, directly analogous to Adaptam's myeloid checkpoint focus.

$186MComparable

Palleon Pharmaceuticals

United States · palleonpharma.com ↗

Glycoimmunology company targeting Siglecs and other glycan-sensing immune receptors, essentially the same scientific approach as Adaptam's glyco-immune checkpoint antibodies.

$148MComparable

Verseau Therapeutics

United States · www.verseautx.com ↗

Developed antibodies to repolarize immunosuppressive tumor-associated macrophages, matching Adaptam's focus on immunosuppressive myeloid cells.

$54.3MComparable

Surface Oncology

United States · www.surfaceoncology.com ↗

Venture-backed developer of antibody therapies targeting myeloid and other immunosuppressive mechanisms in the tumor microenvironment, similar target biology to Adaptam.

$35MComparable